QurAlis Corp Forays Into Agreement with Eli Lilly To Develop QRL-204

QurAlis Enterprise (QurAlis) reported that it has gone into a exclusive license agreement with Eli Lilly and Company (Lilly) in which QurAlis is conceding Lilly worldwide privileges to create and popularize QRL-204, a possibly top tier splice...

Aurigene Announces the Opening of Its Biologics Facility

Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft.in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed...

BD to Acquire Edwards Lifescience's Critical Care Product Group

BD (Becton, Dickinson and Company), a main worldwide medical technology firm, and Edwards Lifesciences reported a conclusive arrangement under which BD will buy Edwards' critical Care product group (Critical Care), a worldwide forerunner in...

Massive Bio and Un Ensayo Para Mi Team up to Transform Oncology Clinical Trial

Massive Bio, an international leader in AI-driven oncology solutions, and Un Ensayo Para Mi (UEPM), Latin America's foremost clinical trial search portal, are pleased to announce an expanded collaboration. This agreement will expand Massive Bio's...

US FDA Nods Moderna's an mRNA Respiratory Syncytial Virus Vaccine

Moderna, Inc, a bitotechnology firm, reported that the US Food and Medication Organization (FDA) has sanctioned mRESVIA (mRNA-1345), a mRNA respiratory syncytial vaccine (RSV) immunization, to protect adults of 60 years and more established from...

Nxera Pharma and PrecisionLife Expand R&D Agreement into New Therapeutic Area

Nxera Pharma Co. Ltd and PrecisionLife, the Causal AI medication organization, report the development of their key Research and development partnership into auto-immune disorders with the possibility to distinguish new medication focuses for the...

© 2024 India Pharma Outlook. All Rights Reserved.